Search Weight Loss Topics:

Page 204«..1020..203204205206..210220..»

Home » Long Term Weight Loss » Page 204

WASHINGTON, DC--(Marketwire -05/16/12)- Thanks to two recent studies published in The New England Journal of Medicine, researchers and surgeons have established a tangible link between bariatric surgery and the treatment of type 2 diabetes. Doctors with the Bluepoint Surgical Group, a team of bariatric surgeons in Northern, VA and Washington, DC, say the new findings suggest weight loss procedures are the most effective therapies for type 2 diabetes in obese and morbidly obese patients and should be considered sooner and more often by patients battling with the disease. The Bluepoint Surgical Group says it is encouraged by the results of these trials and hopes they help patients find the most successful treatments for type 2 diabetes on their return to a healthier life.

As the first head-to-head studies to compare bariatric surgery versus medical therapy, The New England Journal of Medicine reports that bariatric surgery procedures such as gastric banding or gastric sleeve have proven to be superior to medical treatment such as pharmaceuticals in producing the remission of type 2 diabetes. One study, conducted by the Cleveland Clinic, shows within one year type 2 diabetes remission rates with bariatric surgery were 40%, compared to 12% for patients treated with the best pharmacotherapy available. A similar two-year study from the Catholic University of Rome, Italy and New York-Presbyterian/Weill Cornell Medical Center experienced remission rates of about 85% for bariatric surgery (75% gastric bypass, 95% biliopancreatic diversion) and zero for medical therapy in patients with BMI greater than 35. Dr. Amir Moazzez and Dr. Denis Halmi of the Bluepoint Surgical Group say they have seen similar results from their patients who have undergone surgical treatment through weight loss surgery in Washington, DC.

Dr. Halmi and the rest of the Bluepoint Surgical Group say the implications of the two studies will have enormous effects on the future of diabetes treatment. While weight loss surgery procedures have always been known to produce significant results in life expectancy (89% improvement according to the latest study from the American Society for Metabolic and Bariatric Surgery), he says patients are also able to reduce the risk of more serious health complications such as heart disease, stroke, hypertension, and now diabetes, a correlation he is eager to explore both at his practice and through further research.

"Research like this helps patients make informed decisions about bariatric surgery. The article here adds credence to the fact that the surgery does more for the patient than just aid in weight loss, if often times reduces other life-threatening conditions the patient may have," says Dr. Halmi.

Because of the gravity of the decision to undergo weight loss surgery, the Bluepoint Surgical Group strongly urges patients to consult with a board-certified and experienced bariatric surgeon before deciding on a procedure, whether it be a gastric bypass or revisional bariatric surgery. Dr. Halmi says through partnership with a dedicated and knowledgeable practice, patients can make a serious difference in their lives. Now equipped with further evidence pointing towards the benefits of bariatric procedures, he adds that he is excited about the future of weight loss surgery and hopes to continue pursuing the highest quality care for his patients in eliminating both type 2 diabetes and obesity.

About Denis J. Halmi, MD, FACS

Dr. Denis Halmi completed his surgical residency at the Brooklyn Hospital Center in New York. Board-certified in general surgery, he has completed over 1,500 gastric bypass surgeries and over 100 laparoscopic gastric bands. Dr. Halmi is the Medical Director of the Weight Loss Surgery Center at Potomac Hospital and a designated Center of Excellence Surgeon by the American Society for Metabolic and Bariatric Surgery.

About the Bluepoint Surgical Group

As a Designated Center of Excellence by the American Society of Bariatric Surgeons, the Bluepoint Surgical Group is comprised of a team of bariatric, general, and laparoscopic surgeons focusing on a range of procedures including colon/rectal surgery, weight loss procedures, and several plastic surgery options. Doctors with the practice have performed over 2000 weight loss operations and also offer long term weight management assistance programs through dietary education, nutritional counseling, and support groups.

The Bluepoint Surgical Group has three locations in the Washington, DC area: 3620 Joseph Siewick Drive Suite 200 in Fairfax, VA, reachable at (703) 620-3211; 2280 Opitz Blvd Suite 320 in Woodbridge, VA, reachable at (703) 878-7610; and 125 Hospital Center Blvd Suite 207 in Stafford, VA, reachable at (540) 318-6135. It can also be contacted online via the website bluepointgroup.com or the Bluepoint Surgical Group Facebook page.

Read this article:
Washington, DC Weight Loss Surgeons Discuss New Link Between Obesity Surgery and Diabetes Treatment

By Jordo Bivona - May 14, 2012 | Tickers: ARNA, OREX, PFE, VVUS | 0 Comments

Jordo is a member of The Motley Fool Blog Network -- entries represent the personal opinions of our bloggers and are not formally edited.

Within the next year, VIVUS (NASDAQ: VVUS) may make the transition from a development stage start-up with no product revenue to a full-fledged pharmaceutical company with two approved drugs in large markets.

Vivus is on the verge of marketing drugs for some of the most common chronic conditions affecting world populations, including obesity, diabetes, sleep apnea and male erectile dysfunction (ED). The company is developing Qnexa for the first three indications. It has tested avanafil for ED.

The companys lead drug Qnexa is actually a combination of two drugs, phentermine and topiramate, each of which has been approved for treatment separately. Phentermine is an amphetamine that suppresses appetite, and is already used to treat obesity. Topiramate is an anti-convulsive agent used to treat epilepsy. As an obesity drug, topiramate probably promotes a feeling of satiety.

Weight loss is such a difficult problem because of the way that physiology works. The body runs basically on carbohydrates taken in by the diet or in short term storage as glycogen in the muscles or liver. Excess calories consumed in the diet are converted to triglycerides and stored as fat. But the fat is not used as fuel until the available glycogen has been depleted, which means that if people want to lose fat, they must be willing to function while hungry. Most people arent prepared to endure this discomfort.

Phentermine has a long history; it was part of the infamous fenfluramine/phentermine (fen-phen) combination used to treat obesity back in the 1990s. As the combo was quite successful in promoting weight loss, it became spectacularly popular, spawning weight-loss clinics that prescribed little else. Unfortunately, fenfluramine was shown to cause heart valve problems and pulmonary hypertension and so was withdrawn from the market by the FDA in 1997. At one point, Wyeth (now merged into Pfizer (NYSE: PFE) had set aside $21 billion to cover potential liability.

In December, 2011, Vivus reported the results of its SEQUEL trial of Qnexa, which showed that patients had an average 10% sustained weight loss compared to 1.8% for the placebo group. Earlier EQUIP and CONQUER studies had shown an average 14.7% weight loss.

In February of this year, an FDA panel voted 20-2 to recommend approval of Qnexa for the treatment of obesity in adults. On April 9, the FDA notified Vivus of an extended Prescription Drug User Fee Act (PDUFA) date of July 17, 2012 for its review of the Qnexa New Drug Application. This extension gives time for a full evaluation of the risks of Qnexa. It seems likely that the FDA will approve Qnexa sometime later this year.

The FDA has only approved one drugXenical, marketed by Roche Holding AG (RHHBY.PK) -- for long term weight loss. The agency has not approved a new drug for short term weight loss since 1999. Qnexa has potential competition in Arena Pharmaceuticals (NASDAQ: ARNA) lorcaserin and Contrave, from Orexigen Therapeutics (NASDAQ: OREX).

Excerpt from:
VIVUS Is A Viable Long Term Investment

EAGLE, Idaho, May 13, 2012 (GLOBE NEWSWIRE) -- Ellison Chiropractic in Eagle, Idaho is using Facebook to enhance patient communications. The practice regularly updates its Facebook page with wellness tips, health news, healthy meal recipes for long-term weight loss, and motivational messages. Patients can also learn more about the practice's different services, including non-invasive pain management and massage therapy.

Eagle chiropractor Dr. Craig Ellison and his wellness care team are using social media to enhance patient communications. The practice is active on Facebook, regularly posting messages for patients that range from health news updates to stress management tips.

"Wellness care is at the core of our practice," said Dr. Craig Ellison. "Our goal is to not only help patients heal after an injury, but also to provide them with the resources that they need to truly thrive. An important part of this mission is regular patient communications. We may not see our patients every day, or even every month, but through Facebook, we can easily keep in touch and share important wellness information."

Dr. Ellison emphasized that Facebook is a unique way to draw together a diverse community that's united by their passion for well-being and good health. The wellness center provides a variety of treatments, ranging from massage therapy to weight loss assistance and nutritional counseling. While these patients are all ages and come from many walks of life, according to the chiropractor, the practice's Facebook page has fostered a strong community that's committed to having health that lasts a lifetime.

"Facebook is an amazing tool for bringing our patients together to form a supportive community that's dedicated to wellness," said Dr. Ellison. "This support can really make a difference for our patients' success."

In addition to news articles and blog posts, the practice regularly shares daily inspiration quotes. "In our busy lives, it's easy to let stress overwhelm our daily routines. Stress is a major cause of chronic illness, weight gain and a serious impediment to overall well-being. A short inspirational quote, message or success story is the perfect way to remind our patients to stay focused on their long-term health goals."

The practice also posts patient care specials on Facebook, such as its recent "New Patient Referral Program." Existing patients who refer friends, family members or coworkers will now receive two complimentary movie tickets or a $20 account credit.

Ellison Chiropractic serves the Eagle, Meridian and Boise communities. The practice provides non-invasive pain management, including the Activator method of adjusting, to help patients heal after a sports injury or car accident injury. As part of the practice's commitment to wellness care, the center also provides massage therapy, lifestyle counseling, and nutritional counseling for long-term weight loss.

Prospective patients may learn more about wellness care by visiting the practice's Facebook page, https://www.facebook.com/pages/Ellison-Family-Chiropractic.

Follow this link:
Eagle Chiropractor Uses Facebook to Encourage Patients Towards Better Health

Allergan Inc. is facing a federal subpoena concerning its controversial weight-loss surgical device, Lap-Band.

Lap-Band is implanted around the stomach to curb an obese persons appetite. It is designed to promote rapid weight loss but has been associated with a growing number of unexpected complications and side effects blamed not only on the device but also on the surgeons implanting it.

According to a Bloomberg report, the subpoena against Allergan has been sourced to the Dept. of Health and Human Services and concerns a recent Congressional call for a hearing to discuss the safety of Lap-Band after a report in Archives of Surgery associated the devices with an extremely high failure rate and a link to long term complications. That study found that about half of all Lap-Band recipients were contemplating a removal of the devices after just six years and nearly 40 percent of patients were bound to suffer long term pain and injuries rooted to the devices.

Earlier this year, despite growing evidence that Lap-Band could be defective and dangerous by design and that a vast number of surgeons havent been well-versed in proper procedures for implanting them, the Food and Drug Administration approved the surgery for people with less severe cases of obesity, potentially putting thousands more people at risk of similar injuries.

In Southern California, the Lap-Band and so-called boutique surgical centers created almost exclusively to implant these devices has been tied a growing controversy. The 1-800-GET-THIN billboard promotion in that area of the state has been stopped after it was learned the surgeons at associated surgery centers were not implanting them properly and had caused at least five deaths since 2009. The surgery centers implanting the devices in California were accused of not providing adequate warning of the risks associated with Lap-Band.

In addition to that risk, the design of Lap-Band has also been linked to serious complications, including erosion of the band through the stomach wall, stretching the esophagus, stretching the stomach pouch, stomach pain, gastroesophageal reflux disease, difficulty swallowing, nausea and vomiting.

These complications likely will lead to a life of pain and discomfort followed by possible repeated revision surgeries to adjust Lap-Band, or a surgery to remove the device far sooner than expected.

Lap-Band was first approved in 2001 for the treatment of morbid or serious obesity, for people at least 100 pounds overweight or for those with a Body Mass Index of 40 or greater. Prospective patients with lower BMI were also candidates for Lap-Band if they were suffering from a related condition such as heart disease which meant their obesity only increased their risks of suffering other related complications. An amended approval of Lap-Band earlier this year lower the minimum BMI for surgery candidates and put less restrictions on the severity and amount of related conditions a patient could have before receiving the device.

See more here:
Allergan Hit with Federal Subpoena Over Lap-Band Weight Loss Device

Portland, OR (PRWEB) May 08, 2012

Doctors of Weight Loss expert & co-founder, Dr. Emma Patterson, is sponsoring a contest in which one inspirational individual will receive a LAP-BAND procedure and one year of follow-up care, compliments of her practice, Oregon Weight Loss Surgery. The contest is sponsored by their Band Together for Weight Loss Campaign, which is an educational initiative that aims to educate consumers and healthcare professionals to work together to address the obesity epidemic. Dr. Emma Patterson, CEO and Medical Director of Oregon Weight Loss Surgery said, "this is an exciting contest, and the first of its kind in the Portland area. At Oregon Weight Loss Surgery my entire team is dedicated to helping people change their lives through weight loss surgery. We are excited to get the message out about the current obesity epidemic, and safe and successful treatments for this chronic disease, including bariatric surgery such as the Lap-Band." The goal of the campaign is to accomplish this through a dual focus on prevention and treatment, as well as acceptance of all effective treatments for obesity, including weight-loss surgery for people who are severely obese. Patterson said, "I love my work - its really fun seeing patients enjoy improved health and quality of life. Its particularly fun to be giving away a potentially life-saving surgery."

The contest winner will publicly share their long-term struggle with weight loss in an effort to encourage others struggling with being significantly overweight (generally 100 or more pounds overweight) to reclaim their health and their lives. To enter the Band Together for Weight Loss contest, individuals must submit a full length photo and a short essay (500-word max) explaining how their weight has had an impact on their health and life and why the LAP-BAND System may be the tool to help achieve their weight loss goal. The contest deadline is MAY 11th, 2012. More information about the contest can be found at http://www.oregonweightlosssurgery.com/

About Oregon Weight Loss Surgery and the Band Together for Weight Loss Campaign Oregon Weight Loss Surgery is the leading comprehensive weight loss surgery program serving patients in the Portland area. The program is overseen by Dr. Emma Patterson, who has more than 10 years of experience in weight loss surgery and has performed over 2,500 procedures. The Band Together for Weight Loss Campaign is an educational initiative with the goal of encouraging healthcare professionals and consumers to work together to address the obesity epidemic.

About Doctors of Weight Loss Co-founded by Emma Squillace and Dr. Emma Patterson, http://www.doctorsofweightloss.com is a resource for people who want to educate themselves about obesity and weight loss surgery. Doctors of Weight Loss brings together the top bariatric surgeons in the country to provide information for patients, family members, and healthcare professionals.

Read the original post:
Doctors of Weight Loss Co-Founder, Dr Emma Patterson, Giving Away Lap Band

May 10, 2012 1:43pm

Dr. Tom Lavin performs POSE surgery. (Shana Druckerman/ABC News)

Would you have surgery to lose 30 pounds? A controversial new procedure in weight loss has patients pleased but critics concerned.

In a quaint suburb of New Orleans, women are lining up for a new weight loss surgery called the POSE procedure. Short for Primary Obesity Surgery Endoluminol, the surgery is done outpatient andis incision-less. Dr. Tom Lavin, of Surgical Specialists, is one of only a few surgeons in the United States who is offering the procedure. He invited us down to see a surgery on one of his patients.

Theres a big difference between this new option and other, more common forms of bariatric surgery like gastric bypass, lap band, or sleeve gastrectomy. POSE is being marketed to women who want to lose 20 to 50 pounds as opposed to a typical weight loss surgery patient who drops 100 to 150 pounds. With the POSE procedure, everything is done through the mouth. An endoscope and surgical tools are used to pinch sections of the stomach, primarily the fundus area, and then sutured to make the stomach smaller. The size of cavity, according to Lavin, is typically reduced about 20 percent. His patients are reporting not only weight loss, but also fewer cravings.

Dr. Lavin wanted to make it clear that POSE has not worked for all of his patients. Heconceded that 15 to 20 percent are not affected by the procedure. And weight re-gain, just like with any other bariatric procedure, he says, is also a possibility.

When my producer and I raised this story in a staff meeting, several female colleagues were ready to sign up. POSE is promising news to a population of women (and men) who would normally never be considered for other bariatric procedures, but who still battle, through diet and exercise, to lose weight and keep it off.

But before you book your ticket to the bayou state you should know this: No long-term studies have been done in the U.S. to test the safety and effectiveness of the procedure. The device that is used for the surgery has been approved for other uses by the FDA, but does not yet have the sign off for weight loss surgery.

Other members of the bariatric community wont touch it without further study. Dr. Shawn Garber of New York Bariatrics warned, You are putting needles through the patients stomach, you are putting a device down through the esophagus, there are risks. And to put someone through the risk of those things without any proven benefit is definitely controversial.

In answer to colleagues, Lavin has this to say, When I came into surgery in the early 90s, everything was done open. Then people started doing things laparoscopically and it was a little questionable at first and they didnt know how is this going to go, and of course it changed everything.

Read more:
New Weight Loss Surgery: POSE Performed Through the Mouth

EXTON, Pennsylvania, May 3, 2012 /PRNewswire/ -- ViroPharma Incorporated announced three posters will be presented relating to long term data on Plenadren (hydrocortisone, modified release tablet) on May 7 at the 2012 joint 15th International Congress of Endocrinology and 14th European Congress of Endocrinology (ICE/ECE), held May 5 through 9, in Florence, Italy.

Embargo Lifts on Monday, May 7, at 00:01 hours local Florence time.

Poster Presentations

Poster ID: #78 Presenter: Anna Nilsson Title: An Open, Multi-Centre, Phase IIIb, Long-Term Follow-up Study to Assess the Safety, Tolerability and Efficacy of Once-Daily Oral Dual-Release Hydrocortisone in Patients with Adrenal Insufficiency Time: 18:00 - 19:30 hours local Florence time Location: Padiglione Spadolini - Attico at Fortezza da Basso Link: http://www.endocrine-abstracts.org/ea/0029/ea0029p78.htm [http://www.endocrine-abstracts.org/ea/0029/ea0029p78.htm]

Poster ID: #P50 Presenter: Gudmundur Johannsson Title: Intercurrent Illness Dose Regimen in Adrenal Insufficiency with a Dual-Release Hydrocortisone Formulation Derived from Population Pharmacokinetic Modeling Time: 18:00 - 19:30 hours local Florence time Location: Padiglione Spadolini - Attico at Fortezza da Basso Link: http://www.endocrine-abstracts.org/ea/0029/ea0029p50.htm [http://www.endocrine-abstracts.org/ea/0029/ea0029p50.htm]

Poster ID: #P76 Presenter: Maria Forss Title: Dosing Regimens for Glucocorticoid Replacement Therapy - A Worldwide Patient Survey of Patients with Adrenal Insufficiency Time: 18:00 - 19:30 hours local Florence time Location: Padiglione Spadolini - Attico at Fortezza da Basso Link: http://www.endocrine-abstracts.org/ea/0029/ea0029p76.htm [http://www.endocrine-abstracts.org/ea/0029/ea0029p76.htm]

About Plenadren (hydrocortisone, modified release tablet)

Plenadren is indicated for the treatment of adrenal insufficiency in adults.

Hypersensitivity to the active substance of Plenadren or to any of the excipients may occur. During acute adrenal insufficiency, parenteral administration of hydrocortisone in high doses, together with physiological sodium chloride solution for injection, must be given. Use of Plenadren with potent CYP 3A4 inducers and inhibitors may merit an adjustment of hydrocortisone dosage. High (supra-physiological) dosages of cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. Long-term treatment with higher than physiological hydrocortisone doses can lead to clinical features resembling Cushings syndrome with increased adiposity, abdominal obesity, hypertension and diabetes, and thus result in an increased risk of cardiovascular morbidity and mortality. All glucocorticoids increase calcium excretion and reduce the bone remodeling rate. Patients with adrenal insufficiency on long term glucocorticoid replacement therapy have been found to have reduced bone mineral density. Psychiatric adverse events may occur with systemic glucocorticoids.

The most common adverse reactions observed in clinical studies have been fatigue, gastroenteritis, upper respiratory tract infection, sedation, vertigo and dry eyes.

Read more from the original source:
ViroPharma Announces Upcoming Data Presentation Of Plenadren® (Hydrocortisone, Modified Release Tablet) At 2012 Joint ...

COLUMBUS, Ohio, May 3, 2012 /PRNewswire/ --Oxford Resource Partners, LP (OXF) (the "Partnership" or "Oxford") today announced first quarter 2012 financial results.

Overview

Following a challenging quarter, Oxford's management is highly focused on improving its profitability and liquidity through the actions below:

"We are taking rapid and decisive actions to improve operations," said Oxford's President and Chief Executive Officer Charles C. Ungurean. "We are focused on rightsizing our operations to match the currently challenging market conditions and to improve our profitability and liquidity. We are undertaking specific steps that include the ongoing restructuring of our Illinois Basin operations, which we expect will reduce Oxford's overall cost profile and enhance the productivity of our Northern Appalachian operations. By redeploying idled Illinois Basin equipment to our Northern Appalachian operations and selling excess Illinois Basin equipment, among other actions, we will reduce our planned 2012 capital outlays by $10 million and strengthen our balance sheet."

First Quarter 2012 Results

Net loss for the first quarter of 2012 was $15.8 million, or $0.75 per diluted limited partner unit, compared to a net loss for the first quarter of 2011 of $1.8 million, or $0.08 per diluted limited partner unit. First quarter 2012 results were impacted by impairment and restructuring charges related to the Illinois Basin operations and nonrecurring costs of $8.8 million, or $0.43 per diluted limited partner unit. Excluding these items, net loss for the first quarter of 2012 would have been $7.0 million, or $0.32 per diluted limited partner unit. Adjusted EBITDA(1) was $11.0 million for the first quarter of 2012 as compared to $14.0 million for the first quarter of 2011, impacted by a $4.88 per ton increase in cost of coal sales per ton primarily attributable to $3.8 million in higher diesel fuel costs. Distributable cash flow(1) was $0.1 million for the first quarter of 2012, down $5.4 million from the first quarter of 2011, reflecting the impact of a terminated sales contract, $3.8 million in higher diesel fuel costs and $0.8 million in higher cash interest expense.

(1) Definitions of adjusted EBITDA and distributable cash flow, which are non-GAAP financial measures, and reconciliations to comparable GAAP financial measures, are included in the non-GAAP financial measures table presented at the end of this press release.

Production and Sales Information Summary

Three Months Ended

March 31,

Read more:
Oxford Resource Partners, LP Reports First Quarter 2012 Financial Results

HARTFORD, Conn., May 1, 2012 /PRNewswire/ --Virtus Investment Partners, Inc. (VRTS), which operates a multi-manager asset management business, today reported a record level of total and long-term open-end mutual fund sales and net flows for the first quarter of 2012, and a 130 percent increase in operating income, as adjusted, from the first quarter of 2011.

(Logo: http://photos.prnewswire.com/prnh/20090105/NEM020LOGO )

Operating income, as adjusted, was $16.0 million for the quarter ended March 31, 2012, an increase from $7.0 million in the first quarter of 2011 and from $13.6 million in the fourth quarter of 2011. Operating margin, as adjusted, was 34 percent, compared with 21 percent in the prior year's first quarter and 32 percent in the fourth quarter of 2011. The February 24 launch of the Virtus Global Multi-Sector Income closed-end fund contributed $0.2 million to operating income, as adjusted, which excludes $4.5 million of up-front structuring fees, sales-related compensation, and fund offering costs.

Operating income for the first quarter, which includes $4.5 million of costs related to the closed-end fund launch, was $8.0 million with a margin of 13 percent, compared with $4.4 million and 10 percent in the first quarter of 2011 and $8.2 million with a margin of 15 percent in the fourth quarter of 2011. Net income for the quarter was $5.5 million or $0.68 per diluted share, an increase of 26 percent from $4.3 million or $0.43 per diluted share in the first quarter of 2011. Excluding the costs related to the fund launch, operating income and net income for the first quarter of 2012 would have been $12.4 million and $8.1 million, respectively. The company reported income tax expense of $3.6 million, at an effective tax rate of 40 percent, of which $3.5 million, or a rate of 38.6 percent, reflects the utilization of deferred tax assets and $0.1 million, or a rate of 1.4 percent, reflects the current tax obligation.

Operating income, as adjusted, and operating margin, as adjusted, are non-GAAP measures that exclude certain non-cash and other items, including the closed-end fund launch costs and transition costs for the Newfleet Multi-Sector team. These measures are further described and reconciled to GAAP measures at the end of the release.

Assets under management were $38.0 billion at March 31, 2012, an increase of 19 percent from March 31, 2011 and 10 percent from December 31, 2011. Long-term assets under management, which exclude cash management products, were $36.2 billion at the end of the first quarter, an increase of 27 percent from March 31, 2011 and 13 percent from December 31, 2011.

Financial Highlights (Unaudited)

(Dollars in thousands, except per share data or as noted)

In evaluating its performance, the company considers certain non-GAAP measures, including operating income, as adjusted, operating margin, as adjusted, operating expenses, as adjusted, and revenue, as adjusted, that are described and reconciled to GAAP-reported amounts in the table at the end of the release. These non-GAAP measures net the distribution and administration expenses against the related revenue and also exclude certain other cash and non-cash items.

Three Months Ended

See original here:
Virtus Investment Partners Announces Financial Results For the First Quarter of 2012

The three things we can control weight, exercise and diet are the principal factors in developing or escalating type 2 diabetes.

No surprise there.

Nor in the conclusion that many people have a genetic pre-disposition to type 2 diabetes.

And whos surprised to learn losing weight is the solution?

Ah, but wait on weight (couldnt resist that!) It may be easier than you think, says Dr. Donald Hensrud, chair of the Division of Preventive, Occupational and Aerospace Medicine and a consultant in the Division of Endocrinology and Nutrition at Mayo Clinic in Rochester, Minn.

His titles are a mouthful, but Hensrud, listed as main author of The Mayo Clinic Diabetes Diet, takes a refreshingly simple look at dieting.

Question: This is one of the easiest diet books to understand and follow. It stresses vegetables, fruits, whole grains, lean sources of protein and healthy fats but its actually fun to read about this.

Answer: The book starts with a two-week program to lose weight in a safe and healthy way and then goes on into a plan to lose 1 to 2 pounds a week until you reach your goal. And then there are the meal planners and recipes and so on.

Q: Very similar to the regular Mayo Clinic diet book. But what I want to mention is the way that you stress exercise. Couple the age of some people with this problem I mean, a person could be well into their 70s when they find out they have type 2 diabetes isnt developing an exercise program a real challenge?

A: Of course. There isnt a perfect answer for everyone either. But everyone must do some type of physical activity. I remember my grandmother, when she was well into her 80s, doing laps around the dining room table. Some of the practical implementation is right up front. Once you see some success, then the rest of the program can be adopted and turned into a long-term lifestyle program.

Continue reading here:
Mayo Clinic doctor provides simple, bite-sized steps to weight loss

Page 204«..1020..203204205206..210220..»

Home » Long Term Weight Loss » Page 204